Clinical observation on Breviscapine in treating hypertension patients complicated with micro-albuminuria of renal impairment.
OBJECTIVE
To evaluate the efficacy of Breviscapine on essential hypertension (EH) patients complicated with micro-albuminuria of renal impairment.


METHODS
Seventy-six EH patients were randomly assigned to the control group and the treated group, the former was given amlodipine, captopril/uropidil and the latter was given in addition Breviscapine intravenously dripped for 2 treatment courses. The indexes of serum creatinine (Cr), blood urea nitrogen (BUN), blood and urinary beta(2)-microglobulin (beta(2)-MG), and quantitative determination of 24 hrs urinary protein were evaluated before and after treatment.


RESULTS
In the control group, compared with before treatment, the quantitative determination of 24 hrs urinary protein got reduced significantly (P < 0.05), while in the treated group, both urinary beta(2)-MG and quantitative determination of 24 hrs urinary protein got lowered significantly (P < 0.05 and P < 0.01). But after treatment, compared with the control group, urinary beta(2)-MG and quantitative determination of 24 hrs urinary protein in the treated group were obviously reduced (P < 0.05).


CONCLUSIONS
Besides lowering blood pressure effectively, Breviscapine could improve the renal function significantly and reduce the urinary micro-albuminuria, hence showing promising effect on renal protection.
Wei
Ling
L
Department of Gerontology, The Fifth Hospital Affiliated to Sun Yat-sen University, Zhuhai, Guangdong Province, China. weiling-sky@163.com
Tan
Jie
J
D000328:Adult; D000368:Aged; D000419:Albuminuria / Q000209:etiology* / Q000503:physiopathology; D017311:Amlodipine / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005419:Flavonoids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005483:Flushing / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D007275:Injections, Intravenous; D007674:Kidney Diseases / Q000209:etiology* / Q000652:urine*; D008297:Male; D008875:Middle Aged; D011507:Proteinuria / Q000209:etiology / Q000503:physiopathology; D001613:beta 2-Microglobulin / Q000652:urine
D000959:Antihypertensive Agents; D005419:Flavonoids; D001613:beta 2-Microglobulin; C061097:breviscapine; D017311:Amlodipine; D002216:Captopril